PKC-activating compounds for the treatment of neurodegenerative diseases
AssigneeCognitive Research Enterprises, Inc.
InventorsThomas J. Nelson, Daniel L. Alkon
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Claims3
A method for reducing neurodegeneration comprising administering to a subject in need thereof an effective amount of at least one compound chosen from a cis-monounsaturated fatty acid ester in which the double bond is replaced by a cyclopropyl group.
Dependencies are inferred from the claim text.